hrp0086fc13.5 | Management of Obesity | ESPE2016

Effects of AZP-531, a First-in-Class Unacylated Ghrelin Analog, on Food-Related Behaviour in Prader-Willi Patients: A Multi-Center, Randomized, Placebo-Controlled Study

Allas Soraya , Caixas Assumpta , Poitou Christine , Coupaye Muriel , Thuilleaux Denise , Lorenzini Francoise , Diene Gwenaelle , Crino Antonino , Illouz Frederic , Grugni Graziano , Delale Thomas , Abribat Thierry , Tauber Maithe

Background: Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by hyperphagia and abnormal behaviours towards food for both of which no approved treatment is available. Elevated plasma acylated ghrelin (AG) documented at all ages in PWS suggest that the ghrelin system may contribute to the pathophysiology of hyperphagia. Administration of unacylated ghrelin and 8-amino acid analog AZP-531 prevents AG-induced food consumption in animals and improves glucose co...

hrp0082p1-d3-128 | Fat Metabolism & Obesity (2) | ESPE2014

Acylated and Unacylated Ghrelin Levels in Children and Young Adults with Prader–Willi Syndrome

Kuppens Renske , Diene Gwenaelle , Bakker Nienke , Molinas Catherine , Faye S , Nicolino Marc , Bernoux Delphine , Delhanty Patric , Jan van der Lelij Aart , Allas Soraya , Julien Michiel , Delale Thomas , Tauber Maithe , Hokken-Koelega Anita

Background: Prader–Willi syndrome (PWS) is characterized by a switch in early childhood from failure to thrive to excessive weight gain and hyperphagia with impaired satiety. The underlying mechanism for this switch may involve hyperghrelinemia, but only poor data exists regarding levels of acylated ghrelin (AG), unacylated ghrelin (UAG), and the AG/UAG ratio in PWS.Objective and hypotheses: To investigate plasma levels of AG and UAG in PWS, compare...